Suppression of IL6/JAK1-mediated PD-L1 glycosylation sensitized anti-Tim3 immune checkpoint blockade (ICB) therapy as manifested by reduced tumor growth and prolonged survival in Hepa1-6 hepatoma-bearing mice [44]. This evidence concerns the gene HAVCR2 and hepatocellular carcinoma.